
Cantor Fitzgerald analysts initates an Overweight rating for Biocryst Pharmaceuticals Inc (BCRX)
Biocryst Pharmaceuticals Inc’s recent filing unveils that its Director Hutson Nancy J unloaded Company’s shares for reported $52780.0 on Dec
Biocryst Pharmaceuticals Inc’s recent filing unveils that its Director Hutson Nancy J unloaded Company’s shares for reported $52780.0 on Dec
Biocryst Pharmaceuticals Inc’s recently made public that its Director Hutson Nancy J unloaded Company’s shares for reported $52780.0 on Dec
Biocryst Pharmaceuticals Inc’s recent filing unveils that its Director Hutson Nancy J unloaded Company’s shares for reported $52780.0 on Dec
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Biocryst Pharmaceuticals Inc’s recently made public that its Director Hutson Nancy J unloaded Company’s shares for reported $52780.0 on Dec
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
BioCryst Pharmaceuticals, Inc. (BCRX) stock prices were up a promising 4.95% as of market close on April 21st, 2021, bringing